Microparticles (MP) are considered to be membrane nano-fragments with 0.05-1 μm diameter having intact vesicular appearance. MPs are produced by various circulating cells and by endothelial cells after their activation or apoptosis. MPs, including the platelet microparticles (PMP) and endothelial microparticles (EMP) are bioactive because of their procoagulant activity, activation of inflammation mechanism, and activation of angiogenesis. The purpose of the current study was to characterize circulating platelet and endothelial MPs in patients with type 2 diabetes mellitus (T2DM) compared to healthy controls, in order to elucidate their role as predictive marker of vascular complications in these patients. To achieve this aim, detection of PMP and EMP by flowcytometer was done using anti CD62E, anti CD62P, anti CD31and anti CD42b monoclonal antibodies. PMP was defined as CD31+/42b+ and CD62P + while EMP was defined as CD31+/42b- and CD62E+. The study involved enrollment of 30 diabetic patients divided in 2 groups , group I includes 15 diabetic patients with no vascular complication ,and group II includes 15 diabetic patients with known cardiovascular complication .15 healthy volunteers were included in the study as a control group . PMP and EMP were significantly higher in diabetic patients compared to the control group with no significance between the 2 diabetic groups. CD62E/CD31+42b- ratio was ≤ 1 suggesting an apoptotic mechanism of EMP generation in diabetic individuals. The significant correlation between EMP (CD62+) and HbA1c indicates that the uncontrolled diabetic patients might be more prone to develop vascular injury and endothelial dysfunction, also the positive significant correlation detected between LDL and EMP( CD31+/CD42-) points to the importance of LDL in inducing arterial stiffness releasing EMP. These results can point to the importance of PMP and EMP as markers for haemostatic activation, and development of thrombotic events.